- In February 2021, BioTherapeutic Labs Corp (BTL) and American CryoStem, a biotechnology company, entered into a strategic collaboration agreement aimed at advancing stem cell research and development. Under the terms of the agreement, BTL will distribute CRYO’s products and services, while the two companies will jointly focus on research and development efforts to refine and enhance protocols utilizing CRYO’s ATCell autologous mesenchymal stem cells alongside BTL’s human umbilical cord-based product offerings. This partnership underscores the growing collaboration between stem cell technology companies, accelerating the development of advanced stem cell therapies and products
- In April 2024, PromoCell GmbH introduced the Cryo-SFM Plus cryopreservation medium, designed to preserve primary cells, stem cells, and established cell lines. This advanced medium enhances cell viability during the cryopreservation process, ensuring the long-term preservation of cell cultures without compromising their functionality. This launch addresses the critical need for effective preservation solutions in stem cell research and storage. By improving the efficiency and reliability of cryopreservation, Cryo-SFM Plus offers significant benefits to stem cell banks, enabling the safe storage of diverse stem cell populations for future therapeutic applications and research
- In January 2024, STEMCELL Technologies, Inc. completed the acquisition of Propagenix Inc., a move that allows STEMCELL to integrate Propagenix's EpiX technology into its product development portfolio for regenerative medicine. This acquisition will enable STEMCELL to create advanced products leveraging EpiX technology, particularly in the field of cell culture and stem cell-based therapies. This strategic acquisition expands STEMCELL’s capabilities in regenerative medicine and stem cell research. By incorporating EpiX technology, STEMCELL is positioned to enhance the development of high-quality stem cell products, which will support the growth of stem cell banking services
- In October 2023, bit.bio, a leader in programming human cells for advanced therapeutic applications, launched its latest product, ioCRISPR-Ready Cells. These cells are specifically designed to assist researchers in creating gene knockouts in human cells, ensuring physiological relevance for more accurate and effective studies. This product offers a valuable tool for advancing gene editing techniques in stem cell research. By facilitating the creation of precise gene knockouts in stem cells, bit.bio’s ioCRISPR-Ready Cells contribute to enhancing the quality of stem cell-based therapies and applications, driving innovation within stem cell banks and their related services
- In September 2023, SKAN Research Trust (SKAN) formed a collaborative partnership with the Wellcome-MRC Cambridge Stem Cell Institute (CSCI) in the UK. The collaboration involves a joint research initiative aimed at exploring the genomic patterns linked to age-related neurodegenerative diseases, with a focus on an Indian cohort. This partnership emphasizes the role of stem cell research in understanding age-related diseases
